Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma
Abstract Background Platinum‐based chemotherapy is the standard of care as first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM‐NPC); however, the prognosis of patients with RM‐NPC remains poor. The aim of this study was to evaluate the role of anti‐epidermal growth factor r...
Main Authors: | Chen Chen, Yixin Zhou, Xuanye Zhang, Sha Fu, Zuan Lin, Wenfeng Fang, Yunpeng Yang, Yan Huang, Hongyun Zhao, Shaodong Hong, Li Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-03-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.2838 |
Similar Items
-
Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
by: Xue-Song Sun, et al.
Published: (2020-08-01) -
Expression of epidermal growth factor receptor in advance stage nonkeratinizing nasopharyngeal carcinoma in West Sumatra, Indonesia
by: Rahman Sukri, et al.
Published: (2018-01-01) -
Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with chemoradiotherapy for induction chemotherapy resistant locally advanced nasopharyngeal carcinoma: A prospective phase II study
by: Xiaoshuang Niu, et al.
Published: (2024-01-01) -
Induction chemotherapy plus nimotuzumab followed
by concurrent chemoradiotherapy for advanced
nasopharyngeal carcinoma
by: Xinmao Song, et al.
Published: (2019-07-01) -
Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
by: Mengping Zhang, et al.
Published: (2020-06-01)